PATENT CLAIM ANALYSIS

Application Number: 16354416
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-07
Patent Classification: ["514", "255050"]

Abstract:
PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.

Claim (Index 10):
The method according to  claim 8  wherein the anticancer agent is an EGFR inhibitor.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 99.0
- Lexical Diversity: 1.4
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15237880', '14818778', '14559889', '10046681', '12502967']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7980419109364387
- 35 USC 102 Novelty (BERT): 0.5686308212592153
- Combined Prediction Score: 0.7751008019687163
- Mean Citation Score: 383.300708
- Max Citation Score: 535.83545
- Similarity Product: 301.9797746322633

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test